BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 25212887)

  • 1. Relapsed and refractory multiple myeloma: new therapeutic strategies.
    Gentili S; Lonial S
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):861-90. PubMed ID: 25212887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment options for relapsed and refractory multiple myeloma.
    Lonial S; Mitsiades CS; Richardson PG
    Clin Cancer Res; 2011 Mar; 17(6):1264-77. PubMed ID: 21411442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel drug combinations for the management of relapsed/refractory multiple myeloma.
    Usmani SZ; Lonial S
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S71-7. PubMed ID: 25486960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel agents for relapsed and/or refractory multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of relapsed and relapsed refractory myeloma.
    Kastritis E; Mitsiades CS; Dimopoulos MA; Richardson PG
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1175-215, x. PubMed ID: 17996594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed/refractory multiple myeloma (MM): a single-centre experience.
    Caravita T; Siniscalchi A; Tendas A; Cupelli L; Ales M; Perrotti A; Niscola P; de Fabritiis P
    Ann Hematol; 2011 Jan; 90(1):115-6. PubMed ID: 20422414
    [No Abstract]   [Full Text] [Related]  

  • 7. Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.
    Boudreault JS; Touzeau C; Moreau P
    Expert Rev Hematol; 2017 Mar; 10(3):207-215. PubMed ID: 28110581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.
    Palumbo A; Larocca A; Falco P; Sanpaolo G; Falcone AP; Federico V; Canepa L; Crugnola M; Genuardi M; Magarotto V; Petrucci MT; Boccadoro M
    Leukemia; 2010 May; 24(5):1037-42. PubMed ID: 20376079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bortezomib-based combination therapy for relapsed or refractory multiple myeloma].
    Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
    Zhonghua Nei Ke Za Zhi; 2008 Feb; 47(2):102-6. PubMed ID: 18683793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pomalidomide in the treatment of relapsed multiple myeloma.
    Forsberg PA; Mark TM
    Future Oncol; 2013 Jul; 9(7):939-48. PubMed ID: 23837756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.
    Richardson PG; Laubach J; Mitsiades C; Schlossman RL; Doss D; Colson K; McKenney ML; Noonan K; Warren DL; Ghobrial IM; Munshi NC; Anderson K
    Oncology (Williston Park); 2010 Mar; 24(3 Suppl 2):22-9. PubMed ID: 20518367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.
    Conticello C; Parisi M; Romano A; Calafiore V; Ancora F; La Fauci A; Consoli ML; Di Raimondo F
    Future Oncol; 2017 Feb; 13(5s):3-6. PubMed ID: 28116941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
    Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M
    Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives for combination therapy to overcome drug-resistant multiple myeloma.
    Catley L; Tai YT; Chauhan D; Anderson KC
    Drug Resist Updat; 2005 Aug; 8(4):205-18. PubMed ID: 16019253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
    Dimopoulos MA; Kastritis E; Christoulas D; Migkou M; Gavriatopoulou M; Gkotzamanidou M; Iakovaki M; Matsouka C; Mparmparoussi D; Roussou M; Efstathiou E; Terpos E
    Leukemia; 2010 Oct; 24(10):1769-78. PubMed ID: 20739955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients.
    Guglielmelli T; Bringhen S; Rrodhe S; Gay F; Cavallo F; Berruti A; Montefusco V; Piro E; Benevolo G; Petrucci MT; Caravita T; Offidani M; Corradini P; Boccadoro M; Saglio G; Palumbo A
    Eur J Cancer; 2011 Apr; 47(6):814-8. PubMed ID: 21334196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effect of cyclophosphamide, thalidomide and dexamethasone combination therapy in relapsed/refractory multiple myeloma].
    Gao W; An N; Chen SL
    Zhonghua Nei Ke Za Zhi; 2006 Mar; 45(3):221-2. PubMed ID: 16624158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.
    Mark TM; Coleman M; Niesvizky R
    Leuk Res; 2014 May; 38(5):517-24. PubMed ID: 24690110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical considerations for multiple myeloma: an overview of recent data and current options.
    Lonial S
    Clin Lymphoma Myeloma; 2008 Aug; 8 Suppl 4():S144-8. PubMed ID: 18952545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide in multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.